The Ronald O. Perelman Department of Dermatology, NYU Langone Health, New York, New York.
Roswell Park Comprehensive Cancer Center, Buffalo, New York.
Clin Transplant. 2019 Dec;33(12):e13736. doi: 10.1111/ctr.13736. Epub 2019 Nov 3.
The International Immunosuppression and Transplant Skin Cancer Collaborative (ITSCC) is an organization of more than 500 physicians and scientists focused on the treatment of cutaneous malignancies following solid organ transplantation and in other forms of immunosuppression. It is well known that solid organ transplant recipients (SOTRs) have an approximate 100-fold increase in the risk of developing skin cancer with consensus guidelines recommending these patients be managed as high risk for local recurrence and metastasis associated with poor outcomes. In September 2018, ITSCC and its European counterpart, the Skin Care in Organ Transplant Patients-Europe (SCOPE), held their biennial scientific retreat in Essex, MA to discuss novel findings in the pathogenesis of cutaneous malignancy including new treatment and prevention strategies in this at-risk population for significant morbidity and mortality from their cutaneous disease. This meeting report is a summary of the novel findings discussed.
国际免疫抑制和移植皮肤癌协作组（ITSCC）是一个由 500 多名医生和科学家组成的组织，专注于治疗实体器官移植后和其他形式免疫抑制下的皮肤恶性肿瘤。众所周知，实体器官移植受者（SOTR）患皮肤癌的风险增加了约 100 倍，共识指南建议将这些患者视为局部复发和转移的高风险，这些风险与不良结局相关。2018 年 9 月，ITSCC 及其欧洲对应组织“器官移植患者皮肤护理-欧洲”（SCOPE）在马萨诸塞州埃塞克斯举行了两年一次的科学务虚会，讨论了皮肤恶性肿瘤发病机制中的新发现，包括针对这一高危人群的新治疗和预防策略，以降低因皮肤疾病导致的显著发病率和死亡率。本会议报告总结了讨论的新发现。
